Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal-Organic Framework Nanoparticles against Breast Cancer.
Animals
Antibiotics, Antineoplastic
/ administration & dosage
Breast Neoplasms
/ drug therapy
Cell Survival
/ drug effects
Disease Models, Animal
Doxorubicin
/ administration & dosage
Drug Liberation
Endocytosis
/ drug effects
Female
Humans
MCF-7 Cells
Metal Nanoparticles
/ chemistry
Metal-Organic Frameworks
/ chemistry
Mice
Mice, Inbred BALB C
Nanoparticle Drug Delivery System
/ chemistry
Photochemotherapy
/ methods
Photosensitizing Agents
/ chemistry
Porphyrins
/ chemistry
Tissue Distribution
/ drug effects
Treatment Outcome
Tumor Burden
/ drug effects
breast cancer
doxorubicin hydrochloride
metal−organic framework materials
photodynamic therapy
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
pubmed:
3
7
2021
medline:
21
1
2022
entrez:
2
7
2021
Statut:
ppublish
Résumé
Breast cancer is one of the most common malignant tumors in women. The existence of multiple breast cancer subtypes often leads to chemotherapy failure or the development of drug resistance. In recent years, photodynamic therapy has been proven to enhance the sensitivity of tumors to chemotherapeutic drugs. Porphyrin-based metal-organic framework (MOF) materials could simultaneously be used as carriers for chemotherapy and photosensitizers in photodynamic therapy. In this paper, doxorubicin hydrochloride (DOX) was loaded in porphyrin MOFs, and the mechanism of the synergistic effect of the DOX carriers and photodynamic therapy on breast cancer was investigated. In vitro and in vivo experiments have shown that MOFs could prolong the residence time of DOX in tumor tissues and promote the endocytosis of DOX by tumor cells. In addition, adjuvant treatment with photodynamic therapy can promote breast cancer tumors to resensitize to DOX and synergistically enhance the chemotherapy effect of DOX. Therefore, this study can provide effective development ideas for reversing drug resistance during breast cancer chemotherapy and improving the therapeutic effect of chemotherapy on breast cancer.
Identifiants
pubmed: 34213912
doi: 10.1021/acs.molpharmaceut.1c00249
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Metal-Organic Frameworks
0
Nanoparticle Drug Delivery System
0
Photosensitizing Agents
0
Porphyrins
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM